Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.

MELA OSORIO MJ; FERRARI L; GOETTE NP; GUTIERREZ MI; GLEMBOTSKY AC; MALDONADO AC; LEV PR; ALVAREZ C; KORIN L; MARTA RF; MOLINAS FC; HELLER PG

EUROPEAN JOURNAL OF HAEMATOLOGY

WILEY-BLACKWELL PUBLISHING, INC

Lugar: Londres; Año: 2015 vol. 1 p. 1 - 8

0902-4441

AbstractBACKGROUND:Anagrelide represents a treatment option for essential thrombocythemia, although its place in therapy remains controversial.AIM:To assess the impact of mutational status in response rates and development of adverse events during long-term use of anagrelide.METHODS:We retrospectively evaluated 67 patients with essential thrombocythemia treated with anagrelide during 68 (4-176) months.RESULTS:Mutational frequencies were 46.3%, 28.3%, and 1.5% for JAK2V617F, CALR and MPL mutations. Anagrelide yielded a high rate of hematologic responses, which were complete in 49.25% and partial in 46.25%, without differences among molecular subsets. The rate of thrombosis during treatment was one per 100 patient-years, without excess bleeding. Anemia was the major adverse event, 30.3% at 5-yr follow-up, being more frequent in CALR + (P < 0.05). Myelofibrotic transformation developed in 14.9% (12.9%, 21%, and 12.5% in JAK2V617F+ , CALR + , and triple-negative patients, respectively, P = NS) and those treated >60 months were at higher risk, OR (95% CI) 9.32 (1.1-78.5), P < 0.01, indicating the need for bone marrow monitoring during prolonged treatment.CONCLUSION:Although CALR + patients were at higher risk of developing anemia, anagrelide proved effective among all molecular subsets, indicating that mutational status does not seem to represent a major determinant of choice of cytoreductive treatment among essential thrombocythemia therapies.